SPOTLIGHT: FDA to examine drug-coated stent safety
Later this week the FDA will tackle the question of whether or not blood clots can form within drug-coated stents designed the prevent the growth of scar tissue. The most important question experts must answer is whether the benefits of drug-coated stents outweigh the small potential risks associated with the devices. Report (WSJ sub. req.)
Be the first to comment
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
- Forecast Model: Antidyslipidemics - Genericization and negative trial data drive market shrinkage
